LB Pharmaceuticals (LBRX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Vor Biopharma (VOR) over the past year, gaining 113.4% versus a loss of 44.4%. LB Pharmaceuticals is the larger company by market cap ($1.09 billion vs $1.08 billion), about 1.0 times the size. On valuation, Vor Biopharma trades at a lower trailing P/E (0.1x vs 338.4x for LB Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | VOR |
|---|---|---|
| Share price | $33.84 | $18.21 |
| Market cap | $1.09B | $1.08B |
| 1-day change | -0.94% | -3.04% |
| YTD return | +53.46% | +43.58% |
| 1-year return | +113.37% | -44.44% |
| 5-year return | — | -93.93% |
| P/E ratio (TTM) | 338.40 | 0.10 |
| EPS (TTM) | $0.10 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $33.50 |
| 52-week low | $14.32 | $6.50 |
| Distance from 52-week high | -32.54% | -45.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.33% | +114.17% |
| Average volume | 341.17K | 992.56K |
| Shares outstanding | 32.26M | 59.16M |
| Employees | 49 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed VOR by 157.8 percentage points over the past year.
- LB Pharmaceuticals trades at a higher earnings multiple (338.4x vs 0.1x trailing P/E).
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
LBRX vs VOR FAQ
Which is bigger, LB Pharmaceuticals or Vor Biopharma?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.09B compared with $1.08B for Vor Biopharma (VOR).
Which stock has performed better over the past year, LBRX or VOR?
LBRX returned +113.37% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, LBRX or VOR?
VOR has the lower trailing P/E at 0.1, versus 338.4 for LBRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are LB Pharmaceuticals and Vor Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for LB Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Vor Biopharma.